Enzo Biochem Overview
Enzo Biochem (ENZ) has a P/E ratio of -1.37, below the Healthcare sector average of 24.78.
Get informed when a big investor buys or sells
+ Follow-1.37
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, ENZ shows a P/E ratio of -1.37. That is below the Healthcare sector average of 24.78. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 24.78. Enzo Biochem is at -1.37, which is lower that average. That is roughly 105.5% below the sector mean. Use the comparison chart on this page to see how ENZ stacks up against individual peers as well.
Investors watch ENZ's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Enzo Biochem's latest reading is -1.37. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Enzo Biochem's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -1.37) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 24.78, while ENZ is at -1.37. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
